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Abstract
Objective: To determine the prescribing patterns for proton pump 
inhibitors and to estimate the economic cost of their use in a group of 
patients affiliated with the Colombian Health System.
Methods: This is a descriptive observational study. Data for analysis 
consisted of prescriptions dispensed between October 1st and October 
31st, 2010 and were collected from a systematic database of 4.2 million 
members. Socio-demographic variables were considered along with 
the defined daily dose, comedication, convenience of the indication for 
proton pump inhibitor use and costs.
Results: In this study, 113,560 prescriptions were dispensed in 89 
cities, mostly to women (57.6%) with a mean age of 54.4 ± 18.7 years; 
the drugs were omeprazole (n= 111,294; 97.81%), esomeprazole (n= 
1.378; 1.2%), lansoprazole (n=524; 0.4%), pantoprazole and rabeprazole. 
The indication for 87,349 of the formulas (76.9%) was justified and 
statistically associated with the use of NSAIDs, antithrombotics, 
corticosteroids, anti-ulcer, antibiotics and prokinetics. No justification 
was found for 26,211 (23.1%) of the prescriptions, which were associated 
with antidiabetics, antihypertensives, hypolipidemics and others (p 
<0.001). The annual justified cost was estimated to be US$ 1,654,701 and 
the unjustified cost was estimated to be U.S. $ 2,202,590, as calculated 
using the minimum reference prices.
Discussion: Each month, the Colombian health system is overloaded 
by unjustified costs that include payments for non-approved indications 
of proton pump inhibitors and for drugs outside the list of essential 
medications. This issue is contributing to rising costs of healthcare in 
Colombia.
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Introduction
Proton pump inhibitors (PPIs) were identified in 1979 and 
approved for the management of acid-peptic disease; they were 
subsequently introduced to the market in 19891. 
Several recent studies comparing omeprazole and ranitidine 
demonstrate the greater effectiveness of omeprazole in the 
treatment of peptic ulcer disease2, upper gastrointestinal bleeding1,2 
and gastroesophageal reflux, leading to an increase in the use of 
PPIs3. In some cases, however, off-label uses increase PPI sales3-5 
and increase the overall costs for healthcare worldwide6,7.
Several conditions justify the use of PPIs, including different 
forms of peptic ulcer disease (Helicobater pylori associated or not), 
functional dyspepsia, gastroesophageal reflux, gastrointestinal 
bleeding prevention in conditions of severe stress and prophylaxis 
for peptic ulcer disease induced by non-steroidal anti inflammatory 
Resumen    
Objetivos.  Determinar los patrones de prescripción de inhibidores 
de la bomba de protones y estimar el costo económico que genera su 
utilización en pacientes afiliados al Sistema General de Seguridad Social 
en Salud de Colombia
Métodos. Estudio descriptivo observacional.  Se analizaron datos de 
fórmulas dispensadas entre 1 y 31 de octubre de 2010 de una base de 
datos sistematizada de 4.2 millones de afiliados. Se consideraron variables 
socio-demográficas, dosis diaria definida, comedicación recibida, 
conveniencia o no del tipo de indicación de IBP y costos.
Resultados. Se dispensaron 113,560 formulas en 89 municipios, 
principalmente a mujeres (57.6%); promedio de edad 54.4±18.7 años; 
los medicamentos fueron omeprazol (n= 111,294, 97.8%), esomeprazol 
(n= 1,378, 1.2%),  lanzoprazol (n= 524, 0.4%), pantoprazol y rabeprazol 
a dosis diarias definidas adecuadas. Se halló justificación en la indicación 
de 87,349 fórmulas (76.9%) asociadas estadísticamente con uso de 
AINEs, antitrombóticos, corticoides, antiulcerosos, antibióticos, 
procinéticos,  y sin justificación 26,211 (23.1%) asociadas a antidiabéticos, 
antihipertensivos e hipolipemiantes y otros (p <0.001). El costo anual 
justificado fue de US$1,654,701 y no justificado de U.S. $2,202,590 
empleando mínimos precios de referencia.
Discusión. Mensualmente se está cargando al sistema de salud 
colombiano con costos no justificados del uso de inhibidores de bomba 
de protones en indicaciones no aprobadas y con medicamentos por fuera 
del listado de esenciales que contribuyen a encarecer la atención sanitaria.
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drugs (NSAIDs) and corticosteroids. However, the use of PPIs has 
begun to extend to pathologies for which they were not designed 
and for which there is insufficient scientific evidence justify their 
use6-8.
The uncontrolled use of PPIs is associated with atrophic 
gastritis, interstitial nephritis, induction of ulcer symptoms, 
thrombocytopenia, osteoporosis and endocrine disorders such 
as gynecomastia and impotence9-12. The probability of adverse 
reactions to PPIs also increases with polymedication and is higher 
in patients with chronic diseases13,14. This is due in part to the 
metabolism of PPIs through cytochrome P450, which leads to 
various drugs interactions by extending their half-life and thereby 
causes harmful systemic effects14.
Countries such as Argentina,  Ireland, Spain and Greece have 
reported significant additional healthcare costs incurred by the 
inappropriate prescription of PPIs.  Indeed, it has been found that 
between 70% and 80% of PPIs prescriptions are for off-label uses 
3,4,6,8. To date, this type of study had not been done in Colombia, 
but is necessary in order to determine the pattern of PPI 
prescriptions and their costs, just as previous research has done for 
antihypertensives, antidiabetics, lipid lowering drugs, anti-tumor 
necrosis factor, antibiotics and antiretrovirals. Studies on all of 
these medications have revealed issues with dosing, indications, 
safety and cost effectiveness within the Colombian Health System 
(SGSSS)15,16.
In order to determine the prescribing patterns of PPIs and 
to calculate the costs generated by their use, this research 
was conducted in an outpatient population of the SGSSS that 
were being treated with these drugs. The implementation of 
information systems in investigating prescribing practices has 
been an essential tool for achieving a greater therapeutic quality 
of the drug prescriptions, contributing in improving the rationale 
use of drugs according to their approved indications.
Materials and Methods
This is a descriptive study that provides an economic analysis of 
PPI prescription patterns in a sample of 4.2 million people that 
represent 20.4% of the patients affiliated with SGSSS and 8.2 % of 
the total population of Colombia. 
These patients were affiliated with 16 different health insurance 
companies (EPS) and 42 different health service providers (IPS) 
across 89 cities of between 20,000 and 7.5 million inhabitants. 
The cities of Barranquilla, Bogota, Bucaramanga, Cali, Cartagena, 
Ibague, Manizales, Medellin and Pereira accounted for 80% of 
the patients. Patients of all ages and of both sexes who received a 
prescription for a PPI between October 1, 2010 and October 31, 
2010 were included in this research sample.
The Department of Pharmacoepidemiology of the company 
that dispenses PPIs helped design a database allowing for the 
collection of certain descriptive variables about the patients using 
these medications, as described below: 
Demographic variables recorded included age, gender, insurance 
company (EPS) provider, and city. Information was also collected 
on the specific PPI drugs used along with their respective doses; 
these drugs were esomeprazole, lansoprazole, omeprazole, 
pantoprazole and rabeprazole. 
Information on comedications was also collected. Pertinent 
comedications included: a) Antihypertensives (ACE inhibitors, 
diuretics, beta blockers, calcium antagonists, prazosin), b) 
antiplatelet agents (acetylsalicylic acid, clopidogrel), c) analgesics 
(acetaminophen, metamizole), d) diabetes medications (insulin, 
metformin, sulfonilureas), e) NSAIDs (ibuprofen and others), f) 
antiemetics (metoclopramide), g) antibiotics for the treatment 
of H. pylori infection (amoxicillin, clarithromycin, azithromycin, 
metronidazole, tetracyclines, levofloxacin), h) corticosteroids 
(prednisolone, and others), i) lipid-lowering drugs (statins, fibrates, 
ezetimibe, cholestyramine), j) other anti-ulcer medications 
(sucralfate, bismuth, antacids, H2 blockers), k) Disease 
modifying anti rheumatic drugs (DMARDs) (methotrexate, and 
others), l) nitrates, m) inotropic agents (digoxin, metildigoxin), 
n)  bisphosphonates, and o) antithyroid /thyroid hormone 
medications (methimazole, propylthiouracil, levotiroxin)15,16. 
Among the PPI-treated patient pool, comedication was used as 
surrogate indicator of chronic disease for the following classes 
of treatment and associated conditions: antihypertensive / high 
blood pressure, antiplatelet /ischemic heart disease, analgesics 
/ pain management, antidiabetic drugs / diabetes mellitus, 
NSAID / inflammatory joint disease, antiemetics / reflux 
or dyspepsia, antibiotics / peptic ulcer disease by H. pylori, 
corticosteroid / inflammatory or autoimmune disease, lipid 
lowering drug / dyslipemia, PPIs or H2 blocker / peptic ulcer 
disease, DMARDs/ rheumatoid arthritis,  nitrate / ischemic 
heart disease, inotropic agent/ heart failure or atrial fibrillation, 
bisphosphonates / osteoporosis, anti thyroid or thyroid hormone/ 
hyper or hypothyroidism. Was accepted as proper use, according 
to comedications as well: NSAID / inflammatory joint disease, 
corticosteroid / inflammatory or autoimmune disease, antibiotics 
/ peptic ulcer disease by H. pylori, antiemetics / reflux or dispepsia. 
All others were considered off label comedications7,17.
The daily defined dose (DDD) was used to measure the level of drug 
dispensation according to World Health Organization (WHO) 
recommendations, expressed as DHD (defined daily doses per 
1000 inhabitants per day). The overall individual costs and the cost 
per 1000 inhabitants / day (CHD= (cost/365 x No. inhabitants) x 
(1,000) for each PPI were used to estimate the economic impact of 
PPI use, using either the minimum or the maximum market price 
of each drug and the benchmark price of the dispensing company 
for different insurance companies (EPS); additionally, the monthly 
and annual costs of these prescriptions were estimated.
The protocol was reviewed by the Bioethics Committee of the 
Universidad Tecnológica of Pereira and the EPS participants, and 
was approved in the category of research without risk. For data 
analysis, we used the statistical package SPSS® Statistics Version 
19 (IBM, USA) for Windows. The descriptive statistics used were 
mean, standard deviation, minimum and maximum values for 
continuous variables and percentages for categorical variables. 
We used the Chi-square test for the comparison of categorical 
variables. Binary logistic regression models were applied using 
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non-justified IPBs as the dependent variable. Statistical significance 
was predetermined to be p< 0.05 (95 % confidence interval).
Results
At least one PPI was dispensed to 113,560 of the total 4.2 million 
users in the database on a monthly basis; of these patients, 65,460 
(57.6%) were women, the mean age was 54.4 ± 18.7 years (range 
1 to 100) and no significant differences in age between men and 
women (men’s mean of 54.5/ vs. women’s mean of 54.3). However, 
women were at greater risk of receiving a PPI for a non-indicated 
reason than men were (OR 1.4, 95% CI: 1.406 to 1.513, p = 0.03). 
The prevalence of PPI use was 3.0% in the studied population. 
Table 1 summarizes the prescribing patterns of the main PPIs 
used in Colombia. The most prescribed PPI in the population was 
omeprazole (20 mg), followed by esomeprazole (20 mg and 40 
mg), but other PPIs were also prescribed in lesser quantities. Of 
all the patients in the study, 107,952 were given a prescription for 
a single PPI (95.1%), while the remaining 5,608 (4.9%) were given 
prescriptions for a combination therapy with another antiulcer 
drug.
Comedication
Among the patients included in this study, 89,468 (78.8%) were 
concomitantly receiving one or more of the following groups 
of drugs that reflected a comorbidity and may cause drug 
interactions with PPIs: antihypertensives (53,552; 47.2% of 
patients), antithrombotics (28,534; 25.1%), analgesics (26,548; 
23.4%), antidiabetic agents (13,019; 11.5%), NSAIDs (11,965; 
10.5%), antiemetic agents (8,267; 7.3%), antibiotics (7,846; 
6.9%); corticosteroids (6,645; 5.9%), lipid lowering drugs (6,135; 
5.4%), DMARDs (3,749; 3.3%), nitrates (1,241; 1.1%), inotropic 
agents (785; 0.7%), bisphosphonates (652; 0.6%), thyroid-based 
medications (187; 0.2%), anti thyroid-based medications (108; 
0.1%) and Cox-2 selective NSAIDs (37; <0.1%). 
A total of 24,092 (21.2%) patients were receiving omeprazole 
exclusively, while 36,182 (31.9%) were receiving one additional 
drug besides omeprazol. A total of 29,733 (26.2%) received two 
additional drugs, 16,628 (14.6%) received three additional drugs, 
5,488 (4.8 %) received four additional drugs, and 1,186 (1.0%) 
received five additional drugs. Other patients received as many as 
six to nine additional drugs (0.2%). The convenience of the use 
of PPIs along with additional drugs was reviewed. Their use was 
indicated in 87,349 (76.8%) of the cases reviewed, but was not 
medically justified in 26,211 (23.1%) of the cases.
In a binary logistic regression analysis, the use of analgesics, 
antidiabetics, antihypertensives, lipid lowering drugs and other 
anti-ulcer drugs were significantly associated with non-indicated 
PPI use. Alternatively, the use of antibiotics, NSAIDs, anti-
emetics, corticosteroids and anti-platelet agents were significantly 
associated with appropriate PPI use (Table 2).
Description by cities 
We also assessed the role of demographic variables in PPI 
prescribing practices among the 89 Colombian cities included in 
this analysis. Because some cities had only a few enrolled patients, 
Table 3 only includes the nine largest cities, which account for 
81.0% of the patients. The same analysis was used for the global 
sum. As shown, no significant differences in the demographic 
variables, frequency of monotherapy use, comedication use and 
DDD were observed between the different cities. However, binary 
logistic regression analysis showed that in Bogota, Barranquilla 
and Pereira, there was a statistically significant association with 
the non-indicated use of PPIs (Table 2).
Economic analysis 
It was found that, on average, the general population consumed 0.9 
DDD of omeprazole, 0.01 DDD of esomeprazole and 0.004 DDD 
of lansoprazole per 1,000 inhabitants per day; this data is of clear 
possible use for future research comparisons. It was determined 
that the cost per 1,000 inhabitants per day for omeprazole was U.S. 
$ 1.2, for esomeprazole U.S. $ 0.6, for lansoprazole U.S. $ 0.2, for 
pantoprazole U.S. $ 0.02, and for rabeprazole U.S. $ 0.01. 
The estimated range in the monthly cost of all justified prescriptions 
was between U.S. $ 137,891, as calculated based on the cheapest 
omeprazole brand on the market (U.S. $ 0.04/pill), and U.S. $ 
7,002,798, as calculated based on the most expensive omeprazole 
brand on the market (U.S. $ 2.9/pill). 
The estimated monthly cost of non-justified prescriptions was 
U.S. $ 183,549 per month, of which 92.6% were for non-indicated 
uses of omeprazole and 7.4% for non-indicated uses of other PPIs. 
The annual justified cost was estimated to be U.S. $ 1,654,441 and 
the annual non-justified cost was estimated to be U.S. $ 2,130,131 
based on minimum prices (Table 4). (Exchange rates were 
representative of the market in October of 2010, and were 1,816 
pesos to 1 dollar). 
Discussion 
Since PPIs are known to be more efficacious than other anti-ulcer 
medications and to have a relatively low toxicity, they have become 
one of the most prescribed drugs worldwide2,6,7. 
Machado-Alba J et al / Colombia Médica - Vol. 44 Nº 1, 2013 (Jan-Mar)
Table 1. Proton Pump Inhibitors prescribing patterns in patients affiliated 
to the Colombian Health Social Security System (SGSSS), October 2010, 
a Female :Male, b Injectable . Gender ratio F:Man[%] ModeOmeprazole 111.2949[7.8] 20 01:04,0 01:00,7Esomeprazol 771[0.7] 20 01:02,9 01:01,3Esomeprazol 607[0.5] 40 1:01 1:09Lansoprazole 474[0.4] 30 01:01,3 01:01,1Omeprazole 33[00.3] 40 - -Omeprazole 85[0.1] 10 01:01,4 1:01Omeprazole 85[0.1] 40 01:01,7 01:00,8Pantoprazole 53[0.05] 40 01:01,1 01:01,3Lanzoprazole 50[0.04] 15 01:01,1 01:01,2Pantoprazole 18[0.02] 20 01:01,1 01:01,3Rabeprazole 17[0.01] 20 01:00,9 01:00,7
27Medication
Prescribed doses (mg/day) Ratio monotherapy:combinationMean24
212330
58424145950
16
The average age of patients enrolled in this study is greater than 
54 years, with a female: male ratio of 1.36:1. Interestingly, female 
patients were found to be at higher risk of receiving an unjustified 
PPI. This may be because women tend to consult physicians more 
often and sooner than do men. 
It is noteworthy that only omeprazole is included in the list of 
essential medicines in Colombia, and as such is considered the 
drug of choice for the treatment of acid peptic disease18. Given 
its placement on the essential medication list, it is understandable 
that 97.8% of patients were treated with omeprazole, while only a 
small group received another PPI. This result differs from other 
reports, which showed increased consumption of PPIs other than 
omeprazole3,19.
Prescribed doses of omeprazole and other PPIs are appropriate in 
the recommended dosage ranges for monotherapy. It is striking 
that about 5.0% of patients received anti-ulcer associations, 
given the limited evidence that their combined use provides 
any additional therapeutic benefits20. However, an evaluation of 
the use of PPIs indicated that 21.2% of patients received only an 
anti-ulcer medication, which is unusual given that 80% to 90% 
of all peptic ulcer diseases are associated with H. pylori infection. 
Such patients should therefore be receiving a PPI in conjunction 
with antibiotics, which was only documented in 6.9% of the cases 
analyzed21.
When assessing the comorbidities leading to the prescription of 
comedications, it was found that hypertension and diabetes are the 
most prevalent comorbidities, with 47.2% and 11.5% of individuals 
affected respectively. Such patients must therefore use drugs that 
are not associated with gastric or duodenal mucosal injury14. 
We also found that frequent use of concomitant antiplatelet 
medications with PPIs causes an increased risk of gastrointestinal 
bleeding22. An increased risk of bleeding is also associated with the 
use of NSAIDs and corticosteroids (10.5% and 5.9% of patients 
received comedication with a PPI, respectively)22,23. The remaining 
comedication patterns reported here, including comedication with 
lipid-lowering drugs and analgesics, have not been justified for 
use as mucosal protectors, especially given the highly aggressive 
nature of these drugs7.
However, it was found that PPIs were used appropriately in 
76.9% of cases, particularly when prescribed along with NSAIDs, 
antiplatelet drugs, corticosteroids, antibiotics to eradicate H. 
pylori and prokinetics.  This percentage is higher than that 
reported in previous studies demonstrating the inappropriate use 
of these drugs in patients with polymedication. The percentage of 
inappropriate PPI use was found to be 72.2% in Spain6, 66.1% in 
Argentina8, 13.0% in France19 and between 25 and 70% in the UK5.
It should be noted that the chronic use of PPIs is associated with an 
increased risk of both atrophic gastritis and community-acquired 
pneumonia24.
The differences in prescribing patterns between the different 
Colombian cities analyzed in this study, which included 
differences in the frequency of use, the percentage of 
monotherapy or comedication, and the DDD (Tables 2 and 3), 
are not surprising given the high variability in healthcare. Indeed, 
differences in prescribing habits are frequently reported in 
pharmacoepidemiological studies15,16. However, physicians in all 
cities typically prescribed an appropriate DDD. The most striking 
finding of this study is that patients in Pereira, Barranquilla 
and Bogota were 19.2, 11.0 and 3.3 times more likely to receive 
a prescription for a non-justified PPI use compared to patients 
from other cities. These variations, important for their clinical, 
social and economic implications, reflect the professional practice 
styles of physicians, which result from both personal factors and 
Machado-Alba J et al / Colombia Médica - Vol. 44 Nº 1, 2013 (Jan-Mar)
Table 2. Variables related to justified and non-justified treatment 
with Proton Pump Inhibitors in binary logistic regression models, 
Colombia October, 2010.
Lower Upper
Medication   NSAIDs -1.565 2.509.369 1 0 0.209 0.197 0.222  Analgesics -2.187 5.008.906 1 0 0.112 0.106 0.119  Antibiotics -0.804 680.65 1 0 0.448 0.421 0.476  Antidiabetics 1.042 691.104 1 0 2.834 2.622 3.063  Antiemetics -1.015 1.021.967 1 0 0.362 0.341 0.386  Antihypertensives -4.01 12.503.635 1 0 0.018 0.017 0.019  Antithrombotic -0.509 200.04 1 0 0.601 0.56 0.645  Antiulcer 0.174 24.898 1 0 1.19 1.111 1.274  Corticoids 0.753 438.496 1 0 2.124 1.979 2.279  Hipolipidemics 2.112 2.421.128 1 0 8.265 7.598 8.991
Gender (Female) 0.378 407.437 1 0 1.459 1.406 1.513
City  Bogotá 1.223 3788.61 1 0 3.397 3.267 3.532  Barranquilla 2.399 5.584.805 1 0 11.016 10.344 11.731  Pereira 2.956 5.927.235 1 0 19.215 17.822 20.717
Variables Ba E,E,b Wald GLc
0.036
ORe
95%CI,f  
0.0310.0310.031
Sig,d
0.040.0320.0360.0360.035
aB: regression coefficient; bEE: standard error; cGL: degrees of freedom; dSig: significance level; eOR: Odds Ratio; f95%CI: 95% confidence interval.
0.0430.019
0.020.0320.038
Table 3.  Comparison of socio-demographic variables and PPI prescription indicators among nine Colombian cities, October, 2010.
Bogotá Barranquilla Cartagena Manizales Pereira Cali Medellin Ibague Bucaramanga Colombia n = 48.981 n = 9.257 n = 6.559 n = 6.383 n = 6.320 n = 6.320 n = 3.928 n = 2.760 n = 1.941 n = 113.560Mean agea 57.7 53.6 55.5 53.2 50.9 58.6 61 51.9 51.1 55.4Women (%) 52.2 58.4 66.4 66.2 63.5 63.5 66.1 68.4 56.6 57.6Monotherapy (%) 21.3 25.4 23.4 17.4 19.1 19.1 17.8 28.7 24.7 21.2Comedication (%) 78.7 74.6 76.6 82.6 80.9 80.9 82.2 71.3 75.3 78.8
Relation between mean dosage and DDDb  Omeprazole 1.2 1 1.2 1.1 1.1 1.2 1.2 1.3 1.2 1.2a n(age) = 20,727 peopleb DDD Omeprazole = 20 mg/day
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differences in medical training15,16.
 
A 2002, an Irish study showed that 10.5% of drug sales covered 
under their health system, equivalent to about € 55 million per 
year, were for the use of the commercial generic brand omeprazole 
25. The findings of the present study are similar, given that when 
extrapolating the value of U.S. $ 3.7 million spent by 8.2% of the 
total Colombian population, the annual cost rises to about U.S. $ 
46 million.
Furthermore, 83.6% of the annual non-justified costs are associated 
with the unjustified use of PPIs not included in the Basic Health 
Plan, meaning they are provided by commercial brands with 
higher retail prices. Simply replacing these brands with the generic 
omeprazole could result in annual savings of approximately 
U.S. $ 1.8 million, which would translate to population-level 
annual savings of about U.S. $ 20.7 million. An additional excess 
spending of U.S. $ 360,000 is caused by the non-justified use of 
generic omeprazole. In the total population, this spending reaches 
an annual cost about U.S. $ 4.4 million. To combat such problems, 
some countries have made proposals detailing the enormous 
savings that the replacement of commercial brands for generic 
brands would generate19.
There are some limitations to the present study and the interpretation 
of certain results therein. All data used for the analysis were 
obtained from dispensation databases rather than directly from 
either patients or prescribers or from a directly-consulted clinical 
record. This limitation will be mitigated by the second phase of 
this research, which will allow further characterization of the 
prescription of anti-ulcer drugs and particularly PPIs. Since this 
study design allows only for the collection of dispensation data, 
it will be necessary to gather additional information in further 
studies, including the indication for PPI use, the range of doses 
used, the incidence of adverse reactions attributable to medication, 
adherence to the recommended treatment, the degree of control 
of acid peptic disease and the associated morbidity levels. It should 
also be noted that the participants in this study represent a captive 
population given a list of specific available drugs, and therefore, 
the findings of this study are only applicable to populations with 
similar characteristics.
Based on the prescribing patterns recorded in this study, it can be 
stated that prescriptions for essential PPIs, mainly for their use 
in anti-ulcer monotherapy, were generally given at appropriate 
doses. Although a small number of patients received a PPI not 
on the list of essential medications, the annual cost of these 
in cases of non-justified use exceeds the entire annual cost of 
appropriately indicated omeprazole. Hypertension, cardiovascular 
risk prevention, pain management and diabetes were the most 
common conditions associated with taking a PPI. Dealing 
with the prescription of PPIs for indications outside of current 
recommendations will require interventions to improve the 
prescribing criteria for patients in the Colombian SGSSS. 
Furthermore, it will be necessary to provide continuing education 
to physicians in order to ensure that they are up to date in 
their management of ulcers, especially with the use of PPIs. 
Such physicians must be trained to prescribe the appropriate 
medications in the appropriate doses, and educated about the 
conditions and comorbidities for which PPI use is indicated or 
contraindicated 7-17. 
Finally, a similar study should address the prescribing practices 
of PPIs to hospitalized patients, as they represent a unique group 
associated with their own specific problems.  
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Table 4. Monthly and annual cost of justified and non-justified PPI prescriptions   in patients affiliated to the Colombian Health Social 
Security System (SGSSS), October 2010.
Medication COP$ USD$a COP$ USD$
JustifiedOmeprazole 87.349 75 250.411.500 137.891 3.004.938.000 1.654.441
Non- justified Omeprazole 20 mg 24.221 75 54.497.250 30.005 653.967.000 360.058 Esomeprazole 20 mg 771 3.866 134.130.870 73.849 1.609.570.440 886,19 Esomeprazole  40 mg 607 4.215 76.755.150 42.259 921.061.800 507.144 Lansoprazole 30 mg 474 3.138 44.622.360 24.568 535.468.320 294.815 Lansoprazole 15 mg 50 1.948 5.844.000 3.217 70.128.000 38.611 Pantoprazole 20 mg 18 4.710 5.086.800 2.801 61.041.600 33.608 Pantoprazole 40 mg 53 5.431 8.635.290 4.754 103.623.480 57.052 Rabeprazole 20 mg 17 7.360 3.753.600 2.067 45.043.200 24,8
Subtotal 26.211 333.325.320 183.549 3.999.903.840 2.130.131
Total Cost 113.560 583.736.820 321.440 7.004.841.840 3.784.572a Foreign Currency Exchange Rate: 1,816  pesos per 1 dollar.  
Monthly Annual
Reference 
price (COP$)
Number 
Prescriptions
18
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